Compare TBPH & WDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | WDI |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 703.9M |
| IPO Year | 2013 | N/A |
| Metric | TBPH | WDI |
|---|---|---|
| Price | $16.34 | $13.44 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.40 | N/A |
| AVG Volume (30 Days) | ★ 282.6K | 157.5K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.80% |
| EPS Growth | ★ 279.13 | N/A |
| EPS | N/A | ★ 1.12 |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.98 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.10 | $12.91 |
| 52 Week High | $21.03 | $15.28 |
| Indicator | TBPH | WDI |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 39.64 |
| Support Level | $16.14 | N/A |
| Resistance Level | $17.21 | $13.70 |
| Average True Range (ATR) | 0.38 | 0.19 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 29.31 | 24.05 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Western Asset Diversified Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income. As a secondary investment objective, the Fund will seek capital appreciation. The fund seeks to achieve its investment objectives by investing, under normal market conditions, across fixed income sectors and securities in seeking to deliver a well-diversified portfolio.